Der er set fald i hæmoglobin, som ikke var klinisk signifikant, hos 1, 7% (dvs almindelig) af de hypertensive patienter med fremskreden diabetisk nyresygdom behandlet med irbesartan.
In 1.7% of hypertensive patients with advanced diabetic renal disease treated with irbesartan, a decrease in haemoglobin*, which was not clinically significant, has been observed.